La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pulike Biological Engineering Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Pulike Biological Engineering ha un patrimonio netto totale di CN¥2.7B e un debito totale di CN¥0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥3.2B e CN¥471.7M. L'EBIT di Pulike Biological Engineering è CN¥128.2M rendendo il suo rapporto di copertura degli interessi -8.9. Ha liquidità e investimenti a breve termine pari a CN¥643.2M.

Informazioni chiave

Rapporto debito/patrimonio netto

CN¥0

Debito

Indice di copertura degli interessi	-6.1x
Contanti	CN¥516.33m
Patrimonio netto	CN¥2.63b
Totale passività	CN¥477.33m
Totale attività	CN¥3.10b

Aggiornamenti recenti sulla salute finanziaria

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28

Recent updates

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Sep 04

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

May 21

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

Apr 28

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Mar 21

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Feb 28

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥1.3B ) di 603566 superano le sue passività a breve termine ( CN¥436.3M ).

Passività a lungo termine: Le attività a breve termine di 603566 ( CN¥1.3B ) superano le sue passività a lungo termine ( CN¥35.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 603566 è esente da debiti.

Riduzione del debito: 603566 non aveva debiti 5 anni fa.

Copertura del debito: 603566 non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: 603566 non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Pulike Biological Engineering Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Recent updates

Investor sentiment improves as stock rises 17%

Now 21% undervalued after recent price drop

Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture

Price target decreased by 13% to CN¥16.24

Now 22% undervalued after recent price drop

Price target decreased by 8.3% to CN¥18.56

Pulike Biological Engineering, Inc. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.40 announced

Investor sentiment deteriorates as stock falls 20%

Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump

Investor sentiment improves as stock rises 19%

Now 26% overvalued after recent price rise

Consensus revenue estimates fall by 13%

Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024

First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.19 in 1Q 2023)

Pulike Biological Engineering, Inc., Annual General Meeting, May 16, 2024

Pulike Biological Engineering, Inc. to Report Q1, 2024 Results on Apr 26, 2024

Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E

Price target decreased by 8.0% to CN¥25.07

Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 15%

Pulike Biological Engineering, Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. (SHSE:603566) announces an Equity Buyback for CNY 200 million worth of its shares.

Pulike Biological Engineering, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased by 7.9% to CN¥28.23

New major risk - Earnings quality

Pulike Biological Engineering, Inc. to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 11%

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2022)

Price target decreased to CN¥28.05

Consensus forecasts updated

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.24 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.55

Investor sentiment improved over the past week

Price target decreased to CN¥26.37

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.20 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.18 in 1Q 2020)

New 90-day low: CN¥20.02

Full year 2020 earnings released: EPS CN¥0.68 (vs CN¥0.34 in FY 2019)

Revenue and earnings beat expectations

New 90-day low: CN¥20.15

New 90-day low: CN¥21.50

New 90-day low: CN¥23.20

New 90-day low: CN¥23.82

Third quarter earnings released

New 90-day high - CN¥31.00

First half earnings released

New 90-day high - CN¥29.65

Pulike Biological Engineering, Inc. to Report First Half, 2020 Results on Aug 31, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane